Research ExplorerPublicationsAmyloid beta peptides in plasma in early diagnosis of Alzhei...

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.

Standard

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. / Lewczuk, P; Kornhuber, J; Vanmechelen, E; Peters, O; Heuser, I; Maier, W; Jessen, F; Bürger, K; Hampel, H; Frölich, L; Henn, F; Falkai, P; Rüther, E; Jahn, Holger; Luckhaus, Ch; Perneczky, R; Schmidtke, K; Schröder, J; Kessler, H; Pantel, J; Gertz, H-J; Vanderstichele, H; de Meyer, G; Shapiro, F; Wolf, S; Bibl, M; Wiltfang, J.

In: EXP NEUROL, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lewczuk, P, Kornhuber, J, Vanmechelen, E, Peters, O, Heuser, I, Maier, W, Jessen, F, Bürger, K, Hampel, H, Frölich, L, Henn, F, Falkai, P, Rüther, E, Jahn, H, Luckhaus, C, Perneczky, R, Schmidtke, K, Schröder, J, Kessler, H, Pantel, J, Gertz, H-J, Vanderstichele, H, de Meyer, G, Shapiro, F, Wolf, S, Bibl, M & Wiltfang, J 2009, 'Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.', EXP NEUROL. <http://www.ncbi.nlm.nih.gov/pubmed/19664622?dopt=Citation>

APA

Lewczuk, P., Kornhuber, J., Vanmechelen, E., Peters, O., Heuser, I., Maier, W., Jessen, F., Bürger, K., Hampel, H., Frölich, L., Henn, F., Falkai, P., Rüther, E., Jahn, H., Luckhaus, C., Perneczky, R., Schmidtke, K., Schröder, J., Kessler, H., ... Wiltfang, J. (2009). Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. EXP NEUROL. http://www.ncbi.nlm.nih.gov/pubmed/19664622?dopt=Citation

Vancouver

Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. EXP NEUROL. 2009.

Bibtex

@article{f141a87629a145deacb7906da7e1e55c,
title = "Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.",
abstract = "We measured concentrations of Abeta peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for Abeta1-42, and 1.8-4.1% for Abeta1-40, inter-assay imprecision for Abeta1-42, Abeta1-40, and Abeta1-42/Abeta1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 4.2-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n=193) had significantly lower Abeta1-42 plasma concentrations (p",
author = "P Lewczuk and J Kornhuber and E Vanmechelen and O Peters and I Heuser and W Maier and F Jessen and K B{\"u}rger and H Hampel and L Fr{\"o}lich and F Henn and P Falkai and E R{\"u}ther and Holger Jahn and Ch Luckhaus and R Perneczky and K Schmidtke and J Schr{\"o}der and H Kessler and J Pantel and H-J Gertz and H Vanderstichele and {de Meyer}, G and F Shapiro and S Wolf and M Bibl and J Wiltfang",
year = "2009",
language = "Deutsch",
journal = "EXP NEUROL",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

RIS

TY - JOUR

T1 - Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.

AU - Lewczuk, P

AU - Kornhuber, J

AU - Vanmechelen, E

AU - Peters, O

AU - Heuser, I

AU - Maier, W

AU - Jessen, F

AU - Bürger, K

AU - Hampel, H

AU - Frölich, L

AU - Henn, F

AU - Falkai, P

AU - Rüther, E

AU - Jahn, Holger

AU - Luckhaus, Ch

AU - Perneczky, R

AU - Schmidtke, K

AU - Schröder, J

AU - Kessler, H

AU - Pantel, J

AU - Gertz, H-J

AU - Vanderstichele, H

AU - de Meyer, G

AU - Shapiro, F

AU - Wolf, S

AU - Bibl, M

AU - Wiltfang, J

PY - 2009

Y1 - 2009

N2 - We measured concentrations of Abeta peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for Abeta1-42, and 1.8-4.1% for Abeta1-40, inter-assay imprecision for Abeta1-42, Abeta1-40, and Abeta1-42/Abeta1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 4.2-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n=193) had significantly lower Abeta1-42 plasma concentrations (p

AB - We measured concentrations of Abeta peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for Abeta1-42, and 1.8-4.1% for Abeta1-40, inter-assay imprecision for Abeta1-42, Abeta1-40, and Abeta1-42/Abeta1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 4.2-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n=193) had significantly lower Abeta1-42 plasma concentrations (p

M3 - SCORING: Zeitschriftenaufsatz

JO - EXP NEUROL

JF - EXP NEUROL

SN - 0014-4886

ER -